{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:03:58Z","timestamp":1763017438092,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.clml.2014.07.006","type":"journal-article","created":{"date-parts":[[2014,7,14]],"date-time":"2014-07-14T12:31:40Z","timestamp":1405341100000},"page":"e7-e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prognostic Factors in Adolescent and Adult Patients With Acute Lymphoblastic Leukemia With Two Protocols of Chemotherapy: A\u00a0Cross-Sectional Study"],"prefix":"10.1016","volume":"15","author":[{"given":"Edilson Diogenes","family":"Pinheiro Junior","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Fernando","family":"Pracchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Beitler de Mauri\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gracia Aparecida","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Enrique","family":"Dorlhiac-Llacer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrezza Bertolaci","family":"Medina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira Deolinda Rodrigues Pereira","family":"Velloso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2014.07.006_bib1","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.1994.12.4.740","article-title":"Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute\/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01","volume":"12","author":"Schorin","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.006_bib2","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood.V80.10.2471.2471","article-title":"Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutives studies of BFM group","volume":"80","author":"Reiter","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.006_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/leu.2009.257","article-title":"Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000","volume":"24","author":"Moricke","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.07.006_bib4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1600-0609.2006.00753.x","article-title":"Initial and late prognostic factors to predict survival in adult acute lymphoblastic leukaemia","volume":"77","author":"Le","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2014.07.006_bib5","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.006_bib6","unstructured":"Five-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age: Table\u00a013.15. Lymphocytic Leukemia. Available at: http:\/\/seer.cancer.gov\/csr\/1975_2010\/browse_csr.php?sectionSEL=13&pageSEL=sect_13_table.15.html. Accessed: Feb 17,\u00a02014."},{"key":"10.1016\/j.clml.2014.07.006_bib7","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1200\/JCO.2004.10.050","article-title":"Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial","volume":"22","author":"Thomas","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.006_bib8","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood-2009-12-261586","article-title":"First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia","volume":"116","author":"Ravandi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.006_bib9","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O","article-title":"Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy","volume":"86","author":"Thomas","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.07.006_bib10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/bmj.1.6107.199","article-title":"Combination chemotherapy for acute lymphoblastic leukaemia in adults","volume":"1","author":"Lister","year":"1978","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2014.07.006_bib11","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1200\/JCO.1988.6.6.1014","article-title":"A\u00a0cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969","volume":"6","author":"Gaynor","year":"1988","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.006_bib12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/blood.V73.1.57.57","article-title":"Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation and maintenance chemotherapy","volume":"73","author":"Hussein","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.006_bib13","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","article-title":"A\u00a0five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811","volume":"85","author":"Larson","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.006_bib14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphoblastic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.006_bib15","article-title":"Improved outcome in high risk and very high risk ALL by risk adapted SCT and in standard risk ALL by intensive chemotherapy in 713 adult ALL patients treated according to the prospective GMALL study 07\/2003","volume":"110","author":"G\u00f6kbuget","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.clml.2014.07.006_bib16","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V99.3.863","article-title":"Treatment of acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMENA ALL 0288 randomized study","volume":"99","author":"Annino","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.006_bib17","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2002.07.116","article-title":"Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia","volume":"20","author":"Linker","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.006_bib18","first-page":"1346","article-title":"Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia: results of the PETHEMA ALL-93 trial","volume":"90","author":"Ribera","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.07.006_bib19","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.006_bib20","article-title":"Reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-STC) for patients with acute lymphoblastic leukemia (ALL): a survey from the European Group for Blood and Marrow Transplantation (EBMT)","volume":"106","author":"Mohty","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.clml.2014.07.006_bib21","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1182\/blood-2003-10-3560","article-title":"Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial","volume":"104","author":"Hunalt","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.006_bib22","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2009-08-231217","article-title":"T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII\/ECOG 2993)","volume":"114","author":"Marks","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.006_bib23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1365-2141.2007.06527.x","article-title":"In\u00a0vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia","volume":"137","author":"Beesley","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.07.006_bib24","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2003-06-2122","article-title":"Clofarabine, a novel nucleoside analog, is active in pediatric patients with advance leukemia","volume":"103","author":"Jeha","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.006_bib25","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2007-03-081364","article-title":"A\u00a0phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias","volume":"110","author":"Karp","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.006_bib26","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1182\/blood-2011-01-329441","article-title":"High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia\/lymphoma offers curative option with subsequent stem cell transplantation","volume":"118","author":"G\u00f6kbuget","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.006_bib27","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/ajh.23167","article-title":"Clofarabine-based chemotherapy\u00a0for\u00a0relapsed\/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma: the Spanish experience","volume":"87","author":"Barba","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2014.07.006_bib28","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.006_bib29","article-title":"Subtype adjusted therapy improves outcome of elderly patients with acute lymphoblastic leukemia (ALL)","volume":"104","author":"Hoelzer","year":"2004","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.clml.2014.07.006_bib30","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases","volume":"52","author":"Raponi","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.07.006_bib31","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.006_bib32","article-title":"Phase II study of the hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD-20 positive acute lymphoblastic leukemia (ALL)","volume":"122","author":"Jabbour","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.clml.2014.07.006_bib33","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/leu.2008.303","article-title":"Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases","volume":"23","author":"Chevallier","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.07.006_bib34","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2006-10-052746","volume":"109","author":"Vignetti","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.006_bib35","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study","volume":"13","author":"Kantarjian","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2014.07.006_bib36","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL","volume":"120","author":"Topp","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.006_bib37","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.07.006_bib38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.thj.6200013","article-title":"The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting\u2014Airlie House, Virginia, November, 1997","volume":"1","author":"Harris","year":"2000","journal-title":"Hematol J"},{"key":"10.1016\/j.clml.2014.07.006_bib39","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.006_bib40","first-page":"1783","article-title":"Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL)","volume":"9","author":"Bene","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.07.006_bib41","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S0889-8588(05)70184-2","article-title":"Cytogenetics in adult acute lymphocytic leukemia","volume":"14","author":"Wetzler","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2014.07.006_bib42","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2007-10-116186","article-title":"Impact of cytogenetics on the outcome of adult lymphoblastic leukemia: results of Southwest Oncology Group 9400 study","volume":"111","author":"Pullarkat","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.006_bib43","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.006_bib44","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1182\/blood.V69.4.1242.1242","article-title":"Improved results of treatment of adult acute lymphoblastic leukemia","volume":"69","author":"Linker","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.006_bib45","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood.V84.9.3122.3122","article-title":"Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: results and conclusions of the multicenter trial ALL-BFM 86","volume":"84","author":"Reiter","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.006_bib46","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL): an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.006_bib47","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1600-0609.2006.00778.x","article-title":"Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"78","author":"Sancho","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2014.07.006_bib48","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","article-title":"Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia","volume":"107","author":"Br\u00fcggemann","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.07.006_bib49","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1365-2141.2005.05544.x","article-title":"Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia","volume":"130","author":"Nachman","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.07.006_bib50","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1200\/JCO.2006.08.6397","article-title":"Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols","volume":"25","author":"Barry","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.006_bib51","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.2003.02.053","article-title":"Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison\u00a0of the French FRALLE-93 and LALA-94 trials","volume":"21","author":"Boissel","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.07.006_bib52","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000351172","article-title":"Hyper-CVAD regimen in routine management of adult acute lymphoblastic leukemia: a retrospective multicenter study","volume":"130","author":"Buyukasik","year":"2013","journal-title":"Acta Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014002663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014002663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:26:27Z","timestamp":1761870387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265014002663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S2152265014002663"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2014.07.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Factors in Adolescent and Adult Patients With Acute Lymphoblastic Leukemia With Two Protocols of Chemotherapy: A\u00a0Cross-Sectional Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2014.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}